

UC Davis

UC Davis Previously Published Works

Title

Corrigendum to 'Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use' [American Journal of Obstetrics and Gynecology 2022;227:871.e1-871.e7]

Permalink

<https://escholarship.org/uc/item/1cv154gm>

Authors

Creinin, Mitchell D
Schreiber, Courtney A
Turok, David K
et al.

Publication Date

2023-07-01

DOI

10.1016/j.ajog.2023.07.011

Peer reviewed

CORRECTION

**Corrigendum to 'Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use'
[American Journal of Obstetrics and Gynecology 2022;227:871.e1-871.e7]**

Mitchell D. Creinin, MD^a; Courtney A. Schreiber, MD, MPH^b; David K. Turok, MD, MPH^c; Carrie Cwiak, MD, MPH^d; Beatrice A. Chen, MD, MPH^e; Andrea I. Olariu, MD, PhD^f

^aDivision of Family Planning, Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA

^bDivision of Family Planning, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA

^cDivision of Family Planning, Department of Obstetrics and Gynecology, The University of Utah, Salt Lake City, UT

^dDivision of Complex Family Planning, Department of Gynecology and Obstetrics, Emory University, Atlanta, GA

^eDivision of Gynecologic Specialties, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh and Magee-Womens Research Institute, Pittsburgh, PA

^fMedicines 360, San Francisco, CA

The authors regret an error in the text of the manuscript. In the Results section, in reference to adverse events and reactions, urinary tract infection rates were reported but not also present in Table 3. The events listed in the table are those considered potentially related to the intrauterine system. As urinary tract infections are not considered by regulatory agencies (and, thus, are not in the label) as potentially related, urinary tract infections were incorrectly included in the text and correctly do not appear in the table. The text should read "The most commonly reported events over 8 or more years of use among the 1714 participants receiving an IUS were vulvovaginal infections with bacteria (n=315, 18.4%) or yeast (n=304, 17.7%)."